Considerations for pharmacoepidemiological analyses in the SARS‐CoV‐2 pandemic
Uloženo v:
| Název: | Considerations for pharmacoepidemiological analyses in the SARS‐CoV‐2 pandemic |
|---|---|
| Autoři: | Christian Fynbo Christiansen, Xavier Kurz, Anton Pottegård, Olaf H. Klungel, Nicholas Moore |
| Přispěvatelé: | Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology |
| Zdroj: | Pottegård, A, Kurz, X, Moore, N, Christiansen, C F & Klungel, O 2020, ' Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic ', Pharmacoepidemiology and Drug Safety, vol. 29, no. 8, pp. 825-831 . https://doi.org/10.1002/pds.5029 Pottegård, A, Kurz, X, Moore, N, Christiansen, C F & Klungel, O 2020, 'Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic', Pharmacoepidemiology and Drug Safety, vol. 29, no. 8, pp. 825-831. https://doi.org/10.1002/pds.5029 Pharmacoepidemiology and Drug Safety |
| Informace o vydavateli: | Wiley, 2020. |
| Rok vydání: | 2020 |
| Témata: | bias, pharmacoepidemiology, Time Factors, Epidemiology, Pneumonia, Viral, Data Collection/methods, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Taverne, Humans, Pharmacology (medical), Pneumonia, Viral/epidemiology, Pandemics, SARS-CoV-2, Data Collection, Pharmacoepidemiology, COVID-19, methodology, Pneumonia, Viral/epidemiology, 3. Good health, Pharmacoepidemiology/organization & administration, Research Design, Coronavirus Infections/epidemiology, Coronavirus Infections |
| Popis: | The coronavirus disease 2019 (COVID‐19) pandemic has triggered several hypotheses regarding use of specific medicines and risk of infection as well as prognosis. Under these unique circumstances, rapid answers require quick engagement in data collection and analyses; however, appropriate design and conduct of pharmacoepidemiologic studies are needed to generate valid and reliable evidence. In this paper, endorsed by the International Society for Pharmacoepidemiology, we provide methodological considerations for the conduct of pharmacoepidemiological studies in relation to the pandemic across eight domains: (1) timeliness of evidence, including the need to prioritise some questions over others in the acute phase of the pandemic; (2) the need to align observational and interventional research on efficacy; (3) the specific challenges related to “real‐time epidemiology” during an ongoing pandemic; (4) what design to use to answer a specific question; (5) considerations on the definition of exposures; (6) what covariates to collect; (7) considerations on the definition of outcomes; and (8) the need for transparent reporting. |
| Druh dokumentu: | Article Review Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1099-1557 1053-8569 |
| DOI: | 10.1002/pds.5029 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/32369865 https://portal.findresearcher.sdu.dk/da/publications/e9a2b199-45f6-48cb-aeed-e6ccd610d9e6 https://dspace.library.uu.nl/handle/1874/410829 https://pure.au.dk/portal/en/publications/edcaadf1-508a-4302-b823-c5d5e77ab0a6 http://www.scopus.com/inward/record.url?scp=85084617176&partnerID=8YFLogxK https://doi.org/10.1002/pds.5029 |
| Rights: | Wiley Online Library User Agreement taverne Wiley TDM |
| Přístupové číslo: | edsair.doi.dedup.....fbd970aec6ac8499b4d18668eb842d59 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | The coronavirus disease 2019 (COVID‐19) pandemic has triggered several hypotheses regarding use of specific medicines and risk of infection as well as prognosis. Under these unique circumstances, rapid answers require quick engagement in data collection and analyses; however, appropriate design and conduct of pharmacoepidemiologic studies are needed to generate valid and reliable evidence. In this paper, endorsed by the International Society for Pharmacoepidemiology, we provide methodological considerations for the conduct of pharmacoepidemiological studies in relation to the pandemic across eight domains: (1) timeliness of evidence, including the need to prioritise some questions over others in the acute phase of the pandemic; (2) the need to align observational and interventional research on efficacy; (3) the specific challenges related to “real‐time epidemiology” during an ongoing pandemic; (4) what design to use to answer a specific question; (5) considerations on the definition of exposures; (6) what covariates to collect; (7) considerations on the definition of outcomes; and (8) the need for transparent reporting. |
|---|---|
| ISSN: | 10991557 10538569 |
| DOI: | 10.1002/pds.5029 |